Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
P Ciracì, M M Germani, F Pietrantonio, et al.
ESMO Open
|
August 22, 2022
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
D Ciardiello, C Chiarazzo, V Famiglietti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
D Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Open
|
June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
D Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
ESMO Open
|
October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy
L Boscolo Bielo, S Napolitano, A Avallone, et al.
ESMO Open
|
February 26, 2022
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
L Cantini, G Mentrasti, G L Russo, et al.
ESMO Open
|
July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis
S Camera, A Vogel, M Rimini, et al.
ESMO Gastrointestinal Oncology
|
May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study
H Vandeputte, A Casadei-Gardini, F Peeters, et al.
ESMO Open
|
November 12, 2025
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)
F Spada, F Gelsomino, M Rinzivillo, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
P Ciracì, M M Germani, F Pietrantonio, et al.
ESMO Open
|
August 22, 2022
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
D Ciardiello, C Chiarazzo, V Famiglietti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
D Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Open
|
June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
D Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
ESMO Open
|
October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy
L Boscolo Bielo, S Napolitano, A Avallone, et al.
ESMO Open
|
February 26, 2022
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
L Cantini, G Mentrasti, G L Russo, et al.
ESMO Open
|
July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis
S Camera, A Vogel, M Rimini, et al.
ESMO Gastrointestinal Oncology
|
May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study
H Vandeputte, A Casadei-Gardini, F Peeters, et al.
ESMO Open
|
November 12, 2025
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)
F Spada, F Gelsomino, M Rinzivillo, et al.
Page
of 3